GENinCode - IPO announcement
GENC
Wed, 21 Jul 2021, 14:00 BST
GENinCode specialises in risk assessment and prediction of cardiovascular disease thrombosis and familial hypercholesterolemia. Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States.
Industry: Health Care
Contact: (+44) 186 5955 847
Oxford Science Park
https://www.genincode.com/
GENinCode CEO Matthew Walls gives us an introduction to the company, reasons behind their IPO and what to expect from them over the next couple of years.
